Leyden Laboratories B.V.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Leyden Laboratories B.V. - overview
Established
2020
Location
Leiden, -, Netherlands
Primary Industry
Biotechnology
About
Founded in 2020, Based in the Netherlands, Leyden Laboratories specializes in developing innovative healthcare solutions focused on infectious diseases, particularly through advanced vaccine candidates aimed at enhancing immunity. It focuses on healthcare innovations targeting infectious diseases and immunology. The company was co-founded by Dinko Valerio, Koenraad Wiedhaup, and Ronald Brus, with Koenraad Wiedhaup serving as CEO. Leyden Laboratories has secured a total of USD 70.
00 mn through four funding rounds, with the most recent investment occurring on June 3, 2025, involving various notable investors such as BlueBird Ventures and GV. Leyden Laboratories specializes in innovative healthcare solutions focused on infectious diseases and immunology. Their core product offerings include advanced vaccine candidates designed to provide robust immunity against various pathogens, leveraging proprietary technology to enhance efficacy and safety profiles. These products are targeted at healthcare providers, government health agencies, and pharmaceutical companies, addressing the global need for effective vaccination strategies across North America, Europe, and parts of Asia.
In 2023, Leyden Laboratories reported an EBITDA of USD -48,846,310. 60. The company generates revenue through strategic partnerships and collaborations with stakeholders in the healthcare sector, including government entities and private healthcare providers. Their business model encompasses contractual agreements that facilitate the development and distribution of vaccine products, with revenue stemming from milestone payments and potential royalties upon market entry.
On June 3, 2025, Leyden Laboratories B. V. raised EUR 20 million in venture debt funding from the European Investment Bank, which will be utilized to further develop intranasal antibody sprays targeting pandemic flu and respiratory threats. Additionally, the company aims to expand its market presence into new regions, although specific countries for expansion have not been disclosed.
Current Investors
F-Prime Capital, GV, Casdin Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.leydenlabs.com
Verticals
HealthTech
Company Stage
Series B
Total Amount Raised
Subscriber access only
Leyden Laboratories B.V. - financials
| Fiscal Year Ended | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|
| Revenue (USD) | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - |
| EBITDA (USD) | (11,688,000) | - | - | - |
| Operating Income (USD) | (11,787,000) | - | - | - |
| Operating Margin | - | - | - | - |
| % EBITDA Margin | - | - | - | - |
| NET Income (USD) | (11,997,000) | - | - | - |
| % Net Margin | - | - | - | - |
Leyden Laboratories B.V. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.